Abstract: A digital emulation of an analog device with tolerance modeling is disclosed. In operation, a model of an analog circuit is provided. The model includes the location of each individual element in the analog circuit. The model also includes a working value for each individual element as well as a tolerance range for each individual element. A randomized working value is then generated for one or more of each individual element based on the tolerance range and the working value. A digital emulation of the analog circuit is performed. The digital emulation uses the randomized working value for one or more of the each individual element and the working value for any remaining of each individual element. The digital emulation is then provided to a user for use in a digital environment.

Abstract: A digital emulation of an analog device with tolerance modeling is disclosed. In operation, a model of an analog circuit is provided. The model includes the location of each individual element in the analog circuit. The model also includes a working value for each individual element as well as a tolerance range for each individual element. A randomized working value is then generated for one or more of each individual element based on the tolerance range and the working value. A digital emulation of the analog circuit is performed. The digital emulation uses the randomized working value for one or more of the each individual element and the working value for any remaining of each individual element. The digital emulation is then provided to a user for use in a digital environment.

Abstract: Described herein are methods for treating breast cancer and for providing a prognosis for metastatic-free survival of breast cancer patients. Aspects relate to treating a patient determined to be at high risk for developing or having metastatic breast cancer comprising administering adjuvant or neoadjuvant therapy to the patient determined to be at high risk for developing or having metastatic breast cancer, wherein the patient was determined to be at high risk for developing or having metastatic breast cancer by determining that the expression level of RKIP was reduced and/or the expression level of one or more of HMGA2, CCL5, TN-FR2, GRN, and CCL7 was elevated in a biological sample from the patient compared to a control non-metastatic tissue sample.